Mebendazole: Difference between revisions
ClaireLewis (talk | contribs) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antiparasitic]] (used to treat nematodes) | *Type: [[Antiparasitic]] (used to treat nematodes) | ||
*Dosage Forms: | *Dosage Forms: Tablet 100mg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: Emverm | ||
==Adult Dosing== | ==Adult Dosing== | ||
*100mg PO BID x 3 days | *100mg PO BID x 3 days | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Mebendazole]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
≥2yo: 100mg PO BID x 3 days | ≥2yo: 100mg PO BID x 3 days | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Mebendazole]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
| Line 45: | Line 71: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 02:39, 20 March 2026
Administration
- Type: Antiparasitic (used to treat nematodes)
- Dosage Forms: Tablet 100mg
- Routes of Administration: Oral
- Common Trade Names: Emverm
Adult Dosing
- 100mg PO BID x 3 days
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Enterobius | 100mg PO once then repeat in 2 weeks | Adult |
Pediatric Dosing
≥2yo: 100mg PO BID x 3 days
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Enterobius | 100mg PO once then repeat in 2 weeks | Pediatric 2 years or older |
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic impairment: may need dose reduction
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Agranulocytosis
- Hepatitis
- Seizure
- Angioedema
Common
- Abdominal pain, diarrhea
Pharmacology
- Half-life: 0.8-11.5h
- Metabolism: Hepatic
- Excretion: Fecal
Mechanism of Action
- Causes parasitic microtubules to degenerate, inhibiting glucose uptake and glycogen storage